KAF156

DRUG4 trials

Sponsors

Novartis Pharmaceuticals

Conditions

Acute Uncomplicated Plasmodium Falciparum MalariaMalariaUncomplicated Plasmodium Falciparum Malaria

Phase 1

Safety and Causal Prophylactic Efficacy of KAF156 in a Controlled Human Malaria Challenge Model

CompletedNCT04072302

Novartis PharmaceuticalsMalaria

Start: 2014-09-15End: 2017-11-29Updated: 2019-08-28

Phase 2

Efficacy, Safety, Tolerability and Pharmacokinetics of KAF156 in Adult Patients With Acute, Uncomplicated Plasmodium Falciparum or Vivax Malaria Mono-infection

CompletedNCT01753323

Novartis PharmaceuticalsMalaria

Start: 2013-03-31End: 2014-08-31Updated: 2018-06-07

Efficacy and Safety of KAF156 in Combination With LUM-SDF in Adults and Children With Uncomplicated Plasmodium Falciparum Malaria

CompletedNCT03167242

Novartis PharmaceuticalsAcute Uncomplicated Plasmodium Falciparum Malaria

Start: 2017-08-02End: 2021-06-28Updated: 2022-02-10

Efficacy, Safety and Tolerability of KAF156 in Combination With Lumefantrine Solid Dispersion Formulation (LUM-SDF) in Pediatric Population With Uncomplicated Plasmodium Falciparum Malaria

CompletedNCT04546633

Novartis PharmaceuticalsUncomplicated Plasmodium Falciparum Malaria

Start: 2021-02-16End: 2024-08-28Updated: 2024-09-25

Related Papers

Distinct gastrointestinal microbial signatures predict parasite levels in controlled Plasmodium infections in both rhesus macaques and humans.

2025-12-191 citations

Pharmacokinetics of Ganaplacide and Lumefantrine in Adults, Adolescents, and Children with <i>Plasmodium falciparum</i> Malaria Treated with Ganaplacide Plus Lumefantrine Solid Dispersion Formulation: Analysis of Data from a Multinational Phase 2 Study

The Journal of Clinical Pharmacology2024-09-294 citations

Ganaplacide (KAF156) plus lumefantrine solid dispersion formulation combination for uncomplicated Plasmodium falciparum malaria: an open-label, multicentre, parallel-group, randomised, controlled, phase 2 trial.

2023-06-1328 citations

Safety, Pharmacokinetics, and Causal Prophylactic Efficacy of KAF156 in a <i>Plasmodium falciparum</i> Human Infection Study

Clinical Infectious Diseases2020-07-0727 citations

Antimalarial Activity of KAF156 in Falciparum and Vivax Malaria

New England Journal of Medicine2016-09-21107 citations